Introduction
============

Bronchiectasis is defined as an irreversible and progressive dilation of the airways due to chronic airway injury.[@b1-copd-13-2041] It is not an independent disease, and many other diseases that affect the defense function of airway could induce bronchiectasis. With the extensive use of high-resolution computed tomography (HRCT), COPD has been considered as one of the etiologies or related diseases of bronchiectasis.[@b1-copd-13-2041] Bronchiectasis has been classified as the comorbidity of COPD in Global Initiative for Chronic Obstructive Lung Disease (GOLD) since 2014.[@b2-copd-13-2041] Thereafter, the updated version of GOLD emphasizes the impact that bronchiectasis has on the natural course and prognosis of COPD.[@b3-copd-13-2041],[@b4-copd-13-2041] In recent years, studies about coexisting COPD and bronchiectasis have caught increasing attention. The content mainly involved the influence of coexisting diseases on acute exacerbation frequency, severity of airflow limitation, prognosis, and characteristics of pathogenic microorganism.[@b5-copd-13-2041]--[@b8-copd-13-2041] Owing to the heterogeneity of both diseases, limited information is known about the relationship between bronchiectasis and different phenotypes of COPD subjects.

Emphysema and chronic bronchitis are two classical phenotypes of COPD, which show different characteristics of symptom, sign, and prognosis.[@b9-copd-13-2041] Previous studies focusing on the phenotype of COPD often excluded bronchiectasis as a confounding factor. Nowadays, coexisting COPD and bronchiectasis has been put forward as not only a comorbidity but also an underlying phenotype.[@b10-copd-13-2041] Just as in COPD, key inflammatory cytokines and proteases, such as neutrophil elastases, were found at elevated levels in bronchiectasis.[@b11-copd-13-2041] This reminds us there may be a common pathway for the two diseases, especially bronchiectasis and emphysema. Emphysema index (EI) measured by computer has been considered as a convenient way to differentiate COPD subjects into emphysema-predominant and non-emphysema-predominant groups.[@b12-copd-13-2041],[@b13-copd-13-2041] In the present study, we explored the relationship between bronchiectasis and emphysema, which was quantified by EI.

Methods
=======

Study population
----------------

In this retrospective study, COPD patients were consecutively retrieved from April 2012 to December 2015 in Qilu Hospital, Shan Dong University. On the basis of GOLD guidelines,[@b14-copd-13-2041] COPD was diagnosed with persistent respiratory symptoms and airflow limitation (post-BD FEV~1~/FVC \<0.70). Patients with chest computed tomography (CT) and pulmonary function test (PFT) at stable status within 12 months were included. An experienced respiratory physician and a respiratory radiologist confirmed the diagnosis of bronchiectasis, according to 1) lack of tapering of bronchi, 2) dilation of bronchi if the internal diameter was larger than that of the adjacent pulmonary artery, or 3) visualization of the peripheral bronchi within 1 cm of the pleural surface.[@b7-copd-13-2041],[@b8-copd-13-2041],[@b15-copd-13-2041] Bronchiectasis in a single pulmonary segment was not included, and lingula was considered as an independent lobe. The Bhalla score was used to quantify the severity of bronchiectasis.[@b16-copd-13-2041] Exclusion criteria include asthma; interstitial lung disease; pneumoconiosis; pneumonia or pulmonary masses \>3 cm on chest CT; bronchiectasis occurring before the age of 40 years, with a history of measles and pertussis, or with a definite history of pulmonary tuberculosis and original site of tuberculosis overlapping with bronchiectasis from CT scans.

Demographic and clinical characteristics were collected, including age, gender, smoking history, history of illness, comorbidities, peripheral blood tests (blood routine, albumin \[ALB\], erythrocyte sedimentation rate, and fibrinogen), HRCT scans, and PFT data.

The study was approved by the Ethics Committee of Qilu Hospital of Shandong University (No 2015091). All the data and analysis were performed anonymously. The Ethics Committee of our hospital agreed that for retrospective studies written informed consent from participants was not required.

PFT
---

PFTs were performed by experienced technicians according to the American Thoracic Society and European Respiratory Society (ATS/ERS) recommendations.[@b17-copd-13-2041] Computerized spirometer (MasterScreen, Jaeger, Hoechberg, Germany) was used. Parameters including basic information (age, height, weight, and body mass index) and spirometry data (FEV~1~, FVC, FEV~1~% predicted, and FEV~1~/FVC) were collected. Post-BD FEV~1~/FVC \<0.70 was considered as airflow limitation.

HRCT
----

A 64-slice spiral CT scanner (SOMATOM Definition AS; Siemens Healthcare, Erlangen, Germany) was used for chest HRCT. Subjects who followed the procedure of chest CT performed at full inspiration. Tube voltage was 120 kV and tube current varied between 20 and 500 mA by automatic regulation. Exposure time was 0.5 second and matrix size was 512×512 pixels. Consecutive images were reconstructed with 1 mm slice thickness.

Quantitative measurement of emphysema
-------------------------------------

Emphysema was defined by the percentage of voxels below −950 HU (%LAA-950) at inspiration as assessed using Airway Inspector software (Surgical Planning Laboratory at Brigham and Women's Hospital, Boston, MA, USA).[@b13-copd-13-2041] As reported in previous work,[@b12-copd-13-2041],[@b13-copd-13-2041] %LAA-950 exceeding 9.9% was responsible for high EI. Based on the EI value, subjects were divided into two groups: emphysema-predominant group (%LAA-950≥9.9%) and non-emphysema-predominant group (%LAA-950\<9.9%).

Statistical analyses
--------------------

Statistical analyses were performed using SPSS version 19.0 (IBM Corporation, Armonk, NY, USA). Data are presented as mean ± SD for continuous variables and percentage for categorical variables. The Student's *t*-test or Mann--Whitney *U*-test was used for normally distributed values or non- normally distributed values. Considering categorical variables, chi-square test was performed to determine the statistical differences between proportions. The Pearson's *r* coefficient was used to investigate the correlation between the severity of bronchiectasis and airflow limitation or EI. Multivariate logistic regression analysis was performed to identify predictive factors for bronchiectasis in COPD patients. *P*\<0.05 was considered statistically significant.

Results
=======

Participants' characteristics
-----------------------------

As shown in [Figure 1](#f1-copd-13-2041){ref-type="fig"}, a total of 2,791 COPD patients were analyzed retrospectively, 984 patients of whom meet the exclusion criteria or did not have HRCT scans. Another 68 patients meet the exclusion criteria of bronchiectasis. In the end, 1,739 COPD patients were included in the present study. The mean age was 68.57±9.76 years, and 79.8% were male. There were 74.1% current or former smokers. Mean value of FVC, FEV~1.0~, and FEV~1.0~/FVC was 2.63 L, 1.49 L, and 54.94%, respectively. Considering the EI, mean %LAA-950 was 13.58%. Of all the subjects, 8.1% were diagnosed with radiological bronchiectasis. Other corresponding comorbidities are shown in [Table 1](#t1-copd-13-2041){ref-type="table"}.

Characteristics of COPD patients with or without bronchiectasis
---------------------------------------------------------------

Patients were divided into two groups: COPD with (n=140) and without (n=1,599) bronchiectasis groups. As shown in [Table 2](#t2-copd-13-2041){ref-type="table"}, there were less male in the group of subjects with bronchiectasis (72.9% vs 80.4%, *P*=0.034). Patients with both COPD and bronchiectasis had worse status of nutrition (ALB, *P*=0.046), more severe airflow obstruction (FEV~1.0~% predicted, *P*\<0.001), and more extensive emphysema (%LAA-950, *P*=0.011) than patients without bronchiectasis. Regarding comorbidities, more patients had pulmonary hypertension (6.4% vs 2.4%, *P*=0.005) and cor pulmonale (23.6% vs 16.1%, *P*=0.022) in COPD and bronchiectasis coexistence group.

Comparison of characteristics between emphysema-predominant group and non-emphysema-predominant group
-----------------------------------------------------------------------------------------------------

There were 787 subjects with measurable EI in the present study. Based on the %LAA-950 value, patients were divided into emphysema-predominant group (%LAA-950≥9.9%, n=369) and non-emphysema-predominant group (%LAA-950,9.9%, n=418). Subjects in emphysema-predominant group had higher proportion of bronchiectasis (16.5% vs 10.3%, *P*=0.01), higher EI (24.5% vs 4.0%, *P*\<0.001), and more severe airflow limitation (FEV~1~% predicted, 38.0% vs 56.7%, *P*\<0.001). Other clinical characteristics of the two groups are shown in [Table 3](#t3-copd-13-2041){ref-type="table"}.

As shown in [Figure 2](#f2-copd-13-2041){ref-type="fig"}, correlations between the severity of bronchiectasis and airflow limitation or emphysema were also performed. The Bhalla score increased as the severity of airflow limitation (*r*=−0.371, *P*\<0.001) and emphysema increased (*r*=0.226, *P*=0.021).

Predictors of bronchiectasis in COPD subjects
---------------------------------------------

We performed multivariate logistic regression analysis that included sex, age, smokers, ALB, and FEV~1~% predicted in model 1 and sex, age, smokers, ALB, and EI in model 2 to identify factors associated with bronchiectasis among COPD subjects ([Table 4](#t4-copd-13-2041){ref-type="table"}). In the two models, FEV~1~% predicted (OR, 1.636; 95% CI, 1.219--2.197; *P*=0.001) and EI (OR, 1.993; 95% CI, 1.199--3.313; *P*=0.008) were significantly related with the presence of bronchiectasis in COPD subjects.

Discussion
==========

As the importance of chest CT in the assessment of COPD becomes more and more prominent, bronchiectasis is found in 4%--57% of COPD patients.[@b8-copd-13-2041],[@b18-copd-13-2041]--[@b20-copd-13-2041] However, the linkage mechanism underlying two diseases remains unclear. As previously reported by Blasi et al,[@b10-copd-13-2041] three hypothetical conditions might be considered: 1) COPD leads to the development of bronchiectasis on account of airway inflammation or infection; 2) bronchiectasis leads to fixed airflow limitation, which meets the diagnostic criteria of COPD; and 3) bronchiectasis and COPD are independent diseases coexisting in one subject. Identification of the three mentioned conditions is of great significance, which might guide the etiology and therapy of diseases. In the present study, we focused on the first condition. As a result, primary bronchiectasis occurring before the age of 40 years, with a history of measles and pertussis or traction bronchiectasis induced by tuberculosis, was all excluded.

Conflicting results were showed in several studies that the proportion of bronchiectasis in patients with COPD ranged from 4% to 57%.[@b6-copd-13-2041],[@b8-copd-13-2041],[@b20-copd-13-2041] The prevalence of bronchiectasis among COPD subjects was 8.1% in the present research. The main reason for different prevalence might lie in the different inclusion and exclusion criteria of COPD subjects and different sample composition. As shown in previous reports,[@b5-copd-13-2041] proportion of bronchiectasis increases with the severity of GOLD stages. Martinez-Garcia et al reported that 57.2% COPD patients presented with bronchiectasis, while the total number of COPD patients in their study was only 201.[@b7-copd-13-2041] In our research, 1,739 COPD patients were included and there were 49.1% with GOLD stages III and IV. What's more, the conditions of bronchiectasis that are included in research are considerably different. Several studies did not exclude the second condition mentioned earlier.[@b6-copd-13-2041],[@b8-copd-13-2041] Other studies included bronchiectasis caused by tuberculosis traction,[@b18-copd-13-2041] which might occur in subjects without COPD. These reasons may partly explain the disparities in prevalence.

High prevalence of bronchiectasis in COPD patients might correlate with the mechanism of COPD. The development of COPD involves small airway, alveoli, and also pulmonary vessels,[@b3-copd-13-2041],[@b9-copd-13-2041] while the impairment of small airway occurs early.[@b9-copd-13-2041],[@b21-copd-13-2041] Recently, a newly accepted hypothesis was proposed: airway basal cell-specific dysfunction of regeneration and remodeling in susceptible subjects might be the driver of COPD development.[@b22-copd-13-2041],[@b23-copd-13-2041] COPD airway epithelial cells regenerate and differentiate poorly, reducing the function of host defense and airway barrier, which makes it susceptible to infections and results in persistent inflammation and remodeling. The same pathogenesis may also induce the development of bronchiectasis. In this sense, it seems that bronchiectasis can be considered as a part of pathological changes of the airway in COPD subjects.

Comparison between patients with and without bronchiectasis shows that the degree of airflow limitation and frequency of comorbidities were higher, and the extent of emphysema was larger in coexisting patients. This implies that exploring the mechanism of coexisting COPD and bronchiectasis may help clinicians to understand the pathology and pathophysiology of COPD. Given sufficient time course, dysfunction of regeneration in pulmonary parenchyma and airway due to the imbalance of protease/anti-protease may aggravate impairment of lung function.[@b24-copd-13-2041] Importantly, clinicians should pay attention to the clarification and therapy of coexisting COPD and bronchiectasis, especially the treatment for improving lung function and delaying complications.

In the present study, it is the first time that EI is used to investigate the correlation between bronchiectasis and different phenotypes in COPD patients. Subjects are divided into two groups: emphysema-predominant and non-emphysema-predominant groups. It turns out that the proportion of bronchiectasis in emphysema-predominant group is higher than in non-emphysema-predominant one (16.5% vs 10.3%, *P*=0.010). Traditionally, chronic bronchitis, due to the airway mucus hypersecretion, poor drainage, and repeated infections, is more easy to complicate with bronchiectasis. However, data in the present research remind us that correlation between bronchiectasis and emphysema is more close, which is different from previous work.[@b25-copd-13-2041] Explanation of the phenomenon may involve two aspects. On one hand, the degree of airflow limitation is more severe in emphysema-predominant group. Patients with higher GOLD stages have poorer drainage and are more susceptible to infections, which makes them more likely to develop bronchiectasis.[@b19-copd-13-2041] On the other hand, one may consider that the imbalance of protease/anti-protease of emphysema influences the regeneration and remodeling of airway wall.[@b26-copd-13-2041]--[@b28-copd-13-2041] The higher proportion of smokers and larger amount of smoking pack-years in emphysema-predominant group of the present study make this explanation more possible, while the verification of this hypothesis and the investigation of mechanism deserve more attention.

Limitations
===========

The present research has some limitations. First, as a retrospective study, part of the clinical data is incomplete and information bias is unavoidable. Patients took CT examinations under several conditions: examination before operations, voluntary examination, and COPD assessment performed by clinicians. The single-center study also influenced the efficacy of analysis results. However, the number of samples is relatively large, and nonsmokers are also included in our study. Just as described in GOLD 2018,[@b4-copd-13-2041] particulate matter also correlates with the development of COPD. Thus, the source of our sample is representative for the general population. To elucidate the conclusions presented in this article, future prospective study involving multicenter data is needed. Second, accurate etiology examinations of bronchiectasis were not performed. The underlying etiologies of bronchiectasis are complicated, including congenital factors and acquired factors such as tuberculosis. The patients with bronchiectasis as such might develop airflow limitation, which could confuse the diagnosis of COPD. The total study population included in this study fulfilled the GOLD criteria of COPD. Thus, bronchiectasis occurring before the age of 40 years or overlapping with original site of tuberculosis from CT scans was excluded in the present study. Future studies involving different etiologies of bronchiectasis are necessary. Other limitation lies in the fact that it is hard to investigate in depth the linkage mechanism of COPD and bronchiectasis based on available data. Considering the inextricable correlation between emphysema and bronchiectasis in COPD subjects, further studies on molecular mechanisms are closely needed.

Conclusion
==========

COPD patients with concomitant bronchiectasis present poorer lung function and higher risk of complication, which should be considered a phenotype of COPD. The occurrence of bronchiectasis in COPD patients correlates with not only a higher degree of GOLD stage but also a higher EI from CT scans. The underlying mechanism deserves further investigation.
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![Flow diagram of the study.\
**Abbreviations:** CT, computed tomography; EI, emphysema index; HRCT, high-resolution computed tomography.](copd-13-2041Fig1){#f1-copd-13-2041}

![Correlation between the severity of bronchiectasis and airflow limitation or emphysema.\
**Notes:** (**A**) Correlation between Bhalla score and FEV~1~% predicted. (**B**) Correlation between Bhalla score and emphysema index.](copd-13-2041Fig2){#f2-copd-13-2041}

###### 

Characteristics of COPD patients

  Variables                     n=1,739
  ----------------------------- ---------------------
  Age, years                    68.57±9.76
  Sex, male/female, %           79.8/20.2
  BMI, kg/m^2^                  23.42±3.97
  Smokers, n, %                 1,288, 74.1
  Smoking history, pack-years   31.43±30.13
  PFT                           
   FVC, L                       2.63±0.93
   FEV~1~, L                    1.49±0.72
   FEV~1~ % predicted, %        52.80±21.93
   FEV~1~/FVC%, %               54.94±12.61
  GOLD I/II/III/IV, %           12.8/38.1/31.7/17.4
  %LAA-950, %                   13.58±13.26
  Comorbidity, n (%)            
   Tuberculosis                 196 (11.3)
   Ischemic heart disease       421 (24.2)
   Pulmonary hypertension       47 (2.7)
   Cor pulmonale                290 (16.7)
   Hypertension                 537 (30.9)
   Diabetes mellitus            165 (9.5)
   Arrhythmia                   169 (9.7)
   Cancer                       711 (40.9)
   Bronchiectasis               140 (8.1)

**Note:** Data are presented as mean ± SD or number (%).

**Abbreviations:** BMI, body mass index; GOLD, global initiative for chronic obstructive lung disease; %LAA-950, percentage of lung voxels with CT attenuation value below −950 HU; PFT, pulmonary function test.

###### 

Comparison between subjects with and without bronchiectasis

  Variables                     COPD with bronchiectasis, n=140   COPD without bronchiectasis, n=1,599   *P*-value
  ----------------------------- --------------------------------- -------------------------------------- -----------------------------------------------------
  Age, years                    68.3±9.1                          68.6±9.8                               0.497[a](#tfn4-copd-13-2041){ref-type="table-fn"}
  Male, n (%)                   102 (72.9)                        1,285 (80.4)                           0.034[b](#tfn5-copd-13-2041){ref-type="table-fn"}
  BMI, kg/m^2^                  23.4±4.0                          23.4±4.0                               0.872[c](#tfn6-copd-13-2041){ref-type="table-fn"}
  Smokers, n (%)                96 (68.6)                         1,192 (74.5)                           0.099[b](#tfn5-copd-13-2041){ref-type="table-fn"}
  Smoking history, pack-years   29.1±29.1                         31.6±30.2                              0.369[a](#tfn4-copd-13-2041){ref-type="table-fn"}
  Blood tests                                                                                            
   ALB, g/L                     36.7±5.5                          37.7±5.3                               0.046[a](#tfn4-copd-13-2041){ref-type="table-fn"}
   ESR, mm/h                    23.1±19.6                         24.8±23.6                              0.888[a](#tfn4-copd-13-2041){ref-type="table-fn"}
   Fib, g/L                     3.7±1.3                           3.6±2.1                                0.231[a](#tfn4-copd-13-2041){ref-type="table-fn"}
  PFT                                                                                                    
   FVC, L                       2.2±0.8                           2.7±0.9                                \<0.001[a](#tfn4-copd-13-2041){ref-type="table-fn"}
   FEV~1~, L                    1.1±0.5                           1.5±0.7                                \<0.001[a](#tfn4-copd-13-2041){ref-type="table-fn"}
   FEV~1~ % predicted           41.9±17.9                         53.8±22.0                              \<0.001[a](#tfn4-copd-13-2041){ref-type="table-fn"}
   FEV~1~/FVC%                  49.5±12.2                         55.4±12.5                              \<0.001[a](#tfn4-copd-13-2041){ref-type="table-fn"}
  Comorbidity, n (%)                                                                                     
   Tuberculosis                 11 (7.9)                          185 (11.6)                             0.183[b](#tfn5-copd-13-2041){ref-type="table-fn"}
   Ischemic heart disease       31 (22.1)                         390 (24.4)                             0.552[b](#tfn5-copd-13-2041){ref-type="table-fn"}
   Pulmonary                    9 (6.4)                           38 (2.4)                               0.005[b](#tfn5-copd-13-2041){ref-type="table-fn"}
  hypertension                                                                                           
   Hypertension                 38 (27.1)                         499 (31.2)                             0.318[b](#tfn5-copd-13-2041){ref-type="table-fn"}
   Cor pulmonale                33 (23.6)                         257 (16.1)                             0.022[b](#tfn5-copd-13-2041){ref-type="table-fn"}
   Diabetes mellitus            18 (12.9)                         147 (9.2)                              0.156[b](#tfn5-copd-13-2041){ref-type="table-fn"}
  %LAA-950                      15.0±12.0                         13.4±13.4                              0.011[a](#tfn4-copd-13-2041){ref-type="table-fn"}

**Notes:** Data are presented as mean ± SD for continuous variables and percentage for categorical variables.

Analysis by Mann--Whitney *U*-test.

Analysis by chi-square test.

Analysis by Student's *t*-test.

**Abbreviations:** ALB, albumin; BMI, body mass index; ESR, erythrocyte sedimentation rate; Fib, fibrinogen; %LAA-950, percentage of lung voxels with CT attenuation value below −950 HU; PFT, pulmonary function test.

###### 

Comparison of characteristics between emphysema-predominant group and non-emphysema-predominant group

  Characteristics               Emphysema-predominant group, n=369   Non-emphysema-predominant group, n=418   *P*-value
  ----------------------------- ------------------------------------ ---------------------------------------- ------------------------------------------------------
  Age, years                    69.9±9.1                             68.2±10.2                                0.014[a](#tfn9-copd-13-2041){ref-type="table-fn"}
  Male, n (%)                   317 (85.9)                           303 (72.5)                               \<0.001[b](#tfn10-copd-13-2041){ref-type="table-fn"}
  BMI, kg/m^2^                  22.5±4.1                             24.5±3.8                                 \<0.001[a](#tfn9-copd-13-2041){ref-type="table-fn"}
  Smokers, n (%)                299 (81.0)                           277 (66.3)                               \<0.001[b](#tfn10-copd-13-2041){ref-type="table-fn"}
  Smoking history, pack-years   34.3±29.6                            27.0±29.9                                \<0.001[c](#tfn11-copd-13-2041){ref-type="table-fn"}
  Blood tests                                                                                                 
   ALB, g/L                     37.7±4.7                             39.2±4.6                                 \<0.001[a](#tfn9-copd-13-2041){ref-type="table-fn"}
   WBC, 10^9^/L                 8.2±3.2                              7.5±3.0                                  0.002[c](#tfn11-copd-13-2041){ref-type="table-fn"}
   NEU, %                       71.2±14.5                            67.9±14.0                                0.001[a](#tfn9-copd-13-2041){ref-type="table-fn"}
   EOS, %                       1.7±3.0                              2.1±4.8                                  0.007[c](#tfn11-copd-13-2041){ref-type="table-fn"}
   ESR, mm/h                    19.5±19.2                            20.5±18.6                                0.252[c](#tfn11-copd-13-2041){ref-type="table-fn"}
   Fib, g/L                     3.5±1.3                              3.4±1.3                                  0.112[c](#tfn11-copd-13-2041){ref-type="table-fn"}
  PFT                                                                                                         
   FVC, L                       2.3±0.7                              2.6±0.9                                  \<0.001[a](#tfn9-copd-13-2041){ref-type="table-fn"}
   FEV~1~, L                    1.0±0.5                              1.6±0.7                                  \<0.001[c](#tfn11-copd-13-2041){ref-type="table-fn"}
   FEV~1~ % predicted           38.0±17.5                            56.7±19.8                                \<0.001[c](#tfn11-copd-13-2041){ref-type="table-fn"}
   FEV~1~/FVC%                  45.1±10.9                            59.0±10.8                                \<0.001[c](#tfn11-copd-13-2041){ref-type="table-fn"}
  Comorbidity, n (%)                                                                                          
   Tuberculosis                 39 (10.6)                            29 (6.9)                                 0.070[b](#tfn10-copd-13-2041){ref-type="table-fn"}
   Ischemic heart disease       81 (22.0)                            120 (28.7)                               0.030[b](#tfn10-copd-13-2041){ref-type="table-fn"}
   Pulmonary hypertension       19 (5.1)                             8 (1.9)                                  0.013[b](#tfn10-copd-13-2041){ref-type="table-fn"}
   Hypertension                 105 (28.5)                           147 (35.2)                               0.044[b](#tfn10-copd-13-2041){ref-type="table-fn"}
   Cor pulmonale                109 (29.5)                           46 (11.0)                                \<0.001[b](#tfn10-copd-13-2041){ref-type="table-fn"}
   Diabetes mellitus            27 (7.3)                             52 (12.4)                                0.017[b](#tfn10-copd-13-2041){ref-type="table-fn"}
   Bronchiectasis               61 (16.5)                            43 (10.3)                                0.010[b](#tfn10-copd-13-2041){ref-type="table-fn"}
  %LAA-950                      24.5±12.0                            4.0±2.8                                  \<0.001[c](#tfn11-copd-13-2041){ref-type="table-fn"}

**Notes:** Data are presented as mean ± SD for continuous variables and percentage for categorical variables.

Analysis by Student's *t*-test.

Analysis by chi-square test.

Analysis by Mann--Whitney *U*-test.

**Abbreviations:** ALB, albumin; BMI, body mass index; EOS, eosinophil; ESR, erythrocyte sedimentation rate; Fib, fibrinogen; %LAA-950, percentage of lung voxels with CT attenuation value below −950 HU; NEU, neutrophil; PFT, pulmonary function test; WBC, white blood cell.

###### 

Logistic regression analysis for predictors of bronchiectasis among COPD subjects

  Variables            Adjusted (model 1)     Adjusted (model 2)                          
  -------------------- ---------------------- -------------------- ---------------------- -------
  Female               1.413 (0.715--2.789)   0.320                1.390 (0.709--2.725)   0.338
  Age                  0.899 (0.483--1.671)   0.736                0.913 (0.491--1.697)   0.774
  Smokers              0.732 (0.392--1.367)   0.328                0.734 (0.395--1.365)   0.329
  ALB                  0.919 (0.481--1.755)   0.797                0.858 (0.451--1.634)   0.642
  FEV~1~ % predicted   1.636 (1.219--2.197)   0.001                NA                     
  %LAA-950             NA                                          1.993 (1.199--3.313)   0.008

**Abbreviations:** ALB, albumin; NA, not applicable; %LAA-950, percentage of lung voxels with CT attenuation value below −950 HU.
